Search Results
Your search for The ASCO P matches 3761 pages
Showing 101 - 150Hybrid AI Approach With Uncertainty Quantification for Mammography Reading Supports Safe Workload Reduction
Investigators have developed and tested a hybrid reading strategy for screening mammography images with artificial intelligence (AI) that includes reads from radiologists and a stand-alone AI interpretation of mammograms with an uncertainty quantification. According to study findings published in...
New Recommendations Released for Managing Aromatase Inhibitor–Induced Bone Loss
A group of experts from seven professional societies have published a joint position statement in the Journal of Bone Oncology on the management of aromatase inhibitor–associated bone loss (AIBL) as a guide for osteoporosis specialists and oncologists. This position statement acts as an update on...
Neoadjuvant Osimertinib in the Perioperative Setting for Resectable, EGFR-Mutated NSCLC
“Neoadjuvant treatment with osimertinib, with or without chemotherapy, should be considered when planning treatment for patients with resectable, EGFR-mutated, stage II to IIIB non–small cell lung cancer [NSCLC],” according to Jamie E. Chaft, MD, FASCO, of Memorial Sloan Kettering Cancer Center and ...
PSMA PET/CT and Salvage Radiotherapy in Recurrent Prostate Cancer
Use of prostate-specific membrane antigen (PSMA) PET/CT before undergoing salvage radiotherapy was associated with an improved overall survival and biochemical recurrence–free survival compared those who did not receive PSMA PET/CT scanning in male patients with biochemically recurrent prostate...
Studies on EGFR Mutations and NRG1 Fusions Included in ASCO NSCLC Living Guideline Update
ASCO has issued a new update to its living guideline on treatment of stage IV non–small cell lung cancer (NSCLC) with driver alterations based on two recent studies.1 The update, which amends the most recent version published in February 2025, includes a discussion of osimertinib therapy options in ...
Emerging PD-1 Inhibitor Plus Chemotherapy Shows Efficacy in Second-Line Classical Hodgkin Lymphoma
The addition of the PD-1 inhibitor sintilimab to ICE (ifosfamide, carboplatin, and etoposide) chemotherapy appeared to significantly improve the complete remission rate and showed a trend toward improved progression-free survival in second-line classical Hodgkin lymphoma, according to Yuankai Shi,...
Tafasitamab Combined With Lenalidomide and Rituximab Improved Outcomes in Relapsed or Refractory Follicular Lymphoma
Adding tafasitamab-cxix, an anti-CD19 monoclonal antibody, to lenalidomide and rituximab significantly prolonged progression-free survival in patients with relapsed or refractory follicular lymphoma, according to data presented at the 2025 European Hematology Association (EHA) Congress.1 Results...
ASCO Names 2025 Q1, Q2 FASCO Recipients
Launched in 2007 and formerly called the ASCO Statesman Award, the FASCO distinction honors members for their extraordinary volunteer service, engagement, and dedication to American Society of Clinical Oncology and the Association for Clinical Oncology (collectively ASCO). Listed here are the FASCO ...
Glioblastoma: Dual Immunotherapy Plus Radiotherapy in Newly Diagnosed MGMT-Unmethylated Disease
The combination of ipilimumab and nivolumab plus radiation therapy did not lead to an improvement in progression-free survival compared with radiation therapy and temozolomide for patients with newly diagnosed MGMT-unmethylated glioblastoma, according to phase II results of the NRG-BN007 trial...
RSNA Challenge AI Models Enhance Mammography Detection of Invasive Breast Cancer
Various artificial intelligence (AI) algorithms submitted as part of a challenge demonstrated the ability to identify different breast cancers during screening mammography, according to the results of a study published in Radiology. Ensemble models of the top submitted algorithms indicated that the ...
Potential New Second-Line Standard of Care Emerges in Small Cell Lung Cancer
In patients with small cell lung cancer, second-line treatment with the bispecific T-cell engager tarlatamab-dlle (which targets the delta-like ligand 3 [DLL3]) vs standard-of-care chemotherapy appeared to significantly improve overall survival, progression-free survival, and patient-reported...
Use of Cemiplimab as Adjuvant Therapy for High-Risk Cutaneous Squamous Cell Carcinoma
The randomized phase III C-POST trial attempted to learn whether the standard-of-care treatment in advanced cutaneous squamous cell carcinoma—cemiplimab-rwlc, which blocks the PD-1/PD-L1 pathway—could reduce recurrence after definitive local therapy for patients who had high-risk features....
AI Enhances Detection of Missed Breast Cancers on Screening Tomosynthesis
A U.S. Food and Drug Administration (FDA)–cleared artificial intelligence (AI) algorithm was able to detect and correctly localize almost one-third of interval breast cancers in a retrospective evaluation of screening digital breast tomosynthesis (DBT), findings published in Radiology showed. The...
Similar Efficacy, Improved Safety Achieved Without Concurrent Cisplatin for Locoregionally Advanced Nasopharyngeal Cancer
The PD-1 inhibitor toripalimab in combination with an induction chemoradiotherapy regimen free of concurrent cisplatin demonstrated noninferior efficacy and superior safety compared with the same regimen plus concurrent cisplatin in patients with high-risk, locoregionally advanced nasopharyngeal...
Update to ASCO Living Guideline for NSCLC Without Driver Alterations Includes First Comparison of Immunotherapy Options
ASCO has issued a new update to its living guideline regarding therapy for stage IV non–small cell lung cancer (NSCLC) without driver alterations, based on results of three studies published recently.1 The update (the first since a previous version in February 2025) includes discussion of...
Studies on EGFR Mutations and NRG1 Fusions Included in ASCO NSCLC Living Guideline Update
ASCO has issued a new update to its living guideline on treatment of stage IV non–small cell lung cancer (NSCLC) with driver alterations based on two recent studies.1 The update, which amends the most recent version published in February 2025, includes a discussion of osimertinib therapy options in ...
Does Menopausal Hormone Therapy Increase the Risk of Death in Women With BRCA-Mutated Breast Cancer?
The risk of death does not appear to increase with the use of menopausal hormone therapy in women with early-onset, BRCA-mutated breast cancer who began hormone supplementation after diagnosis, based on preliminary data presented during the 2025 ASCO Annual Meeting.1 “Management of early surgical...
Intense Resistance Training for Breast Cancer Survivors With Lymphedema Risk
Resistance training can provide many benefits, including increased muscle mass; decreased adipose tissue; and improved metabolism, bone density, strength, and mobility. However, data are limited on the association between resistance training and the development or exacerbation of lymphedema, a...
Immunotherapy Combination: A Potential New Standard in Triple-Negative Breast Cancer
In the phase III ASCENT-04/KEYNOTE-D19 trial, the combination of the TROP2-directed antibody-drug conjugate sacituzumab govitecan-hziy plus the PD-1 inhibitor pembrolizumab in previously untreated patients with PD-L1–positive advanced triple-negative breast cancer significantly reduced the risk of...
Plenary Highlights Across Tumor Types Reflect Advances in Research, Improvements in Care, and Changes in Practice
The 2025 ASCO Annual Meeting included the presentation of data from more than 7,000 abstracts and clinical trials set to advance research, uncover findings, and in some cases change the standard of practice across multiple tumor types, moving science forward and improving care for the more than 2...
Perioperative Therapy With Durvalumab Plus FLOT: A Potential New Standard of Care in Gastric or Gastroesophageal Junction Cancer
In patients with resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma, perioperative treatment with the checkpoint inhibitor durvalumab in combination with standard chemotherapy significantly reduced the risk of recurrence or death by 29% in the phase III MATTERHORN trial. The...
Short-Term Hormonal Treatment Offers Early Insight Into Tumor Behavior and Resistance for ER+/HER2+ Breast Cancer
How ER-positive, HER2-positive breast cancer tumors respond to a short course of hormonal treatment may help to determine whether more aggressive treatment options are necessary for each patient or not, according to translational findings published in eBioMedicine. Tumor subtype changes after 2...
Upfront Radical Cytoreductive Surgery Extends Progression-Free Survival in Advanced Ovarian Cancer
The TRUST trial is the first phase III randomized study to show improved progression-free survival for primary cytoreductive surgery compared with interval surgery without compromising short-term or long-term quality of life, although the study failed to meet its primary endpoint of overall...
BMI and Cardiovascular Disease Associated With Increased Breast Cancer Risk
Weight-associated risk for developing breast cancer after menopause may be higher among women with cardiovascular disease compared with those without cardiovascular disease and women with or without type 2 diabetes, according to the results of two prospective European cohort studies, which were...
Botulinum Toxin and Scopolamine for Radiation-Induced Salivary Gland Toxicity in Metastatic Prostate Cancer
Injection with botulinum toxin (BTX) type A (IncoA) plus transdermal scopolamine led to the reduction in radiation-induced salivary gland toxicity without compromising PSMA (prostate-specific membrane antigen) tumor uptake in patients with metastatic prostate cancer who were receiving...
Adding the Hepcidin Mimetic Rusfertide to the Standard of Care Yields Benefits in Polycythemia Vera
In patients with polycythemia vera requiring frequent phlebotomies, the investigational hepcidin mimetic rusfertide, given as a weekly subcutaneous injection, more than doubled the clinical response rate and significantly improved quality of life in the global phase III VERIFY study.1 These...
W. Kimryn Rathmell, MD, PhD, FASCO, Selected for Women Who Conquer Cancer Mentorship Award
W. Kimryn Rathmell, MD, PhD, FASCO, has been selected for the prestigious 2025 Hologic, Inc Endowed Women Who Conquer Cancer Mentorship Award. Launched in 2016, the Women Who Conquer Cancer award program honors extraordinary women leaders in oncology and role models who have excelled as mentors...
Chinese Herbal Medicine for Improving Adjuvant Chemotherapy Completion in Patients With Colon Cancer
Guest Editor’s Note: Although guidelines recommend adjuvant combination chemotherapy for patients with stage II and III colon cancer who are at high risk of disease recurrence, fewer than 50% complete treatment because of fear of adverse effects or symptom burden. The herbal formula Jianpi Bushen ...
HLA-Matching Considerations for Hematopoietic Cell Transplantation in Hematologic Malignancies
Besides relapse of the malignant disease, graft-vs-host disease is still one of the greatest concerns, in terms of adverse effects, following a hematopoietic cell transplantation (HCT) in a patient with a hematologic malignancy. To mitigate these concerns, investigators are continually analyzing ...
ASCO Honors Karen Eubanks Jackson of Sisters Network® Inc. With 2025 Patient Advocate Award
Karen Eubanks Jackson, founder and Chief Executive Officer of Sisters Network® Inc. (SNI), has been named the recipient of the 2025 Patient Advocate Award by ASCO, Conquer Cancer, and the ASCO Foundation. The awards ceremony was held during the 2025 ASCO Annual Meeting. (See a video with Ms....
Vepdegestrant vs Fulvestrant in Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer
Based on the findings of the VERITAC-2 trial, treatment with the selective PROTAC (proteolysis targeting chimera) estrogen receptor degrader vepdegestrant yielded statistically significant and clinically meaningful improvement in progression-free survival in patients with ESR1-mutant, estrogen...
In Second-Line Setting, T-DXd Improves Survival Outcomes in HER2-Positive Gastric or Gastroesophageal Junction Cancer
In the phase III DESTINY-Gastric04 trial, use of the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) was compared head to head with the monoclonal antibody ramucirumab and paclitaxel in patients with previously treated, HER2-positive metastatic gastric or gastroesophageal junction...
Updated Results Confirm Benefit of Combination Regimen in BRAFV600E–Mutated Metastatic Colorectal Cancer
Patients with previously untreated BRAF V600E–mutated metastatic colorectal cancer who receive the BRAF inhibitor encorafenib and the EGFR inhibitor cetuximab plus mFOLFOX6 (modified leucovorin, fluorouracil, and oxaliplatin) vs the current standard of care (chemotherapy ± bevacizumab) may live...
Early ESR1 Mutation Detection and Therapy Switch in Advanced Hormone Receptor–Positive, HER2-Negative Breast Cancer
Early detection of an ESR1 mutation, leading to a switch of endocrine therapy, led to an almost doubling in progression-free survival in the SERENA-6 trial, the global registrational study in patients with metastatic breast cancer for the investigational oral selective estrogen receptor degrader...
Silence Is Complicity
On January 20, 2025, newly sworn-in President Donald J. Trump signed Executive Order 14151, “Ending Radical and Wasteful Government DEI Programs and Preferencing,”1 effectively eliminating all diversity, equity, and inclusion (DEI) programs, preferences, and activities across the federal...
Adjuvant Use of Atezolizumab Plus Chemotherapy in DNA Mismatch Repair–Deficient Colon Cancer
For the adjuvant treatment of stage III colon cancer with DNA mismatch repair–deficient (dMMR) tumors, the addition of the checkpoint inhibitor atezolizumab to standard chemotherapy significantly improved disease-free survival in the phase III ATOMIC trial. The results position this approach as a...
Phase III Trial Results Suggest a New Standard of Care in Metastatic HER2-Positive Breast Cancer
In the phase III DESTINY-Breast09 trial, first-line treatment with the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) plus the monoclonal antibody pertuzumab significantly delayed disease progression by more than 1 year—nearly doubling the time of disease control—over standard...
Symptom-Detected Breast Cancers May Be Linked to Higher Mortality and Advanced Disease Risk
Whether a patient’s breast cancer was detected through symptoms or routine screening mammography significantly affected their risk for advanced disease or death, according to a study published recently in Radiology: Imaging Cancer. Patients with symptom-detected breast cancer had higher odds of...
Polatuzumab Vedotin–Based Regimen Improves Overall Survival in Refractory DLBCL
Combining the CD79b-directed antibody-drug conjugate polatuzumab vedotin-piiq with rituximab, gemcitabine, and oxaliplatin (R-GemOx) significantly improved survival outcomes in patients with transplant-ineligible, relapsed or refractory diffuse large B-cell lymphoma (DLBCL), over standard rituximab ...
FDA Approves CD19-Directed Antibody–Based Regimen for Follicular Lymphoma
On June 18, the U.S. Food and Drug Administration approved tafasitamab-cxix (Monjuvi), a CD19-directed cytolytic antibody, with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma. inMIND Trial Efficacy was evaluated in inMIND (ClinicalTrials.gov identifier...
Elevated Cardiac Biomarkers Associated With Increased Cancer Risk
Higher baseline levels of certain cardiac biomarkers were associated with an increased risk of future incidence of cancer, according to findings from a study published in the Journal of the American College of Cardiology: Advances. Higher incidence rates for all cancers were associated with higher ...
Order of CRC Diagnosis May Influence Survival in Patients With Multiple Malignancies
The order of colorectal cancer diagnosis seems to have a significant impact on outcomes in patients with multiple primary malignancies, according to the results of a study of Surveillance, Epidemiology, and End Results (SEER) Program data. Findings from the study were published in the Journal of...
FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable, Locally Advanced Head and Neck Cancer
Yesterday, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) for adults with resectable, locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 [combined positive score (CPS) ≥ 1] as determined by an FDA-approved test, as a single agent ...
Relacorilant and Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer
In the phase III ROSELLA trial—reported at the 2025 ASCO Annual Meeting as well as in The Lancet—Olawaiye et al examined the survival benefit of adding relacorilant to nab-paclitaxel in women with platinum-resistant ovarian cancer. Relacorilant is a first-in-class selective glucocorticoid receptor...
Resectable NSCLC: Overall Survival With Neoadjuvant Nivolumab Plus Chemotherapy
In an analysis from the phase III CheckMate 816 trial reported at the 2025 ASCO Annual Meeting and in The New England Journal of Medicine, Forde et al examined overall survival outcomes with the addition of neoadjuvant nivolumab to platinum-based chemotherapy in patients with stage IB to IIIA...
Elinzanetant for Vasomotor Symptoms From Endocrine Therapy for Breast Cancer
In a phase III trial (OASIS-4) reported at the 2025 ASCO Annual Meeting and in The New England Journal of Medicine, Cardoso et al attempted to determine whether the neurokinin-targeted therapy elinzanetant reduced the risk of vasomotor symptoms from endocrine therapy for patients with hormone...
Nomogram Model May Predict DVT Risk in Patients With Ovarian Cancer
Researchers have developed a nomogram prediction model for the development of deep vein thrombosis (DVT) in patients with epithelial ovarian cancer, according to study results published in Menopause, the journal of The Menopause Society. A number of significant independent risk factors for DVT...
MRD-Guided Treatment in Newly Diagnosed Multiple Myeloma
In a French-Belgian phase III trial (MIDAS) reported at the 2025 ASCO Annual Meeting and in The New England Journal of Medicine, Perrot et al examined the outcomes of treatments guided by measurable residual disease (MRD) status in patients with newly diagnosed multiple myeloma. Study Details In...
Adjuvant Cemiplimab in High-Risk Cutaneous Squamous Cell Carcinoma
In a phase III trial (C-POST) reported at the 2025 ASCO Annual Meeting and in The New England Journal of Medicine, Rischin et al compared disease-free survival outcomes of adjuvant cemiplimab vs placebo in patients with high-risk cutaneous squamous cell carcinoma. Study Details In the trial, 415...
Use of Bispecific Antibody in Older Patients With Relapsed or Refractory Multiple Myeloma
Although treatment with the bispecific antibody teclistamab was approved for patients with relapsed or refractory multiple myeloma, based on the MajesTEC-1 study results, only 15% of patients in the phase I/II trial were aged 75 or older. To learn more about the safety and efficacy of this agent in ...
